Interestingly, however, the phase 3 OAK trial showed an overall survival (OS) advantage for atezolizumab (an anti-PD-L1 antibody) versus docetaxel even in the subgroup with immunohistochemically low or undetectable PD-L1 on tumor cells and immune cells (TC0/IC0)3. Here, CD274 is linked to neoplasm.